By Iain Gilbert
Date: Thursday 30 Oct 2025
(Sharecast News) - Pharmaceutical giant Eli Lilly posted stronger-than-expected third-quarter earnings and revenue on Thursday, fuelled by surging demand for its diabetes drug Mounjaro and weight-loss treatment Zepbound.
| Currency | US Dollars |
| Share Price | $ 924.37 |
| Change Today | $ -13.07 |
| % Change | -1.39 % |
| 52 Week High | $937.44 |
| 52 Week Low | $625.65 |
| Volume | 4,373,438 |
| Shares Issued | 948.17m |
| Market Cap | $876,460m |
| Beta | 0.68 |
| RiskGrade | 179 |
| Strong Buy | 11 |
| Buy | 11 |
| Neutral | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 30 |

| Time | Volume / Share Price |
| 15:59 | 200 @ $923.31 |
| 15:59 | 40 @ $923.31 |
| 15:59 | 80 @ $923.27 |
| 15:59 | 40 @ $923.27 |
| 15:59 | 40 @ $923.27 |
You are here: research